Prothena To Ring NASDAQ Stock Market Opening Bell

DUBLIN, Ireland, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that its President and Chief Executive Officer, Dale Schenk, Ph.D., will ring the NASDAQ Stock Market Opening Bell at 9:30 a.m. EST on Wednesday, February 13, 2013 to celebrate the Company's listing on the NASDAQ Global Market in December.

A live webcast of the ceremony can be accessed at: http://www.nasdaq.com/about/marketsitetowervideo.asx

About Prothena Corporation

Prothena Corporation plc (Nasdaq:PRTA) is a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion, particularly on the discovery and development of potential therapeutic monoclonal antibodies directed specifically to disease-causing proteins. These potential therapies have a broad range of indications, including AL and AA forms of amyloidosis, Parkinson's disease and related synucleinopathies, and novel cell adhesion targets involved in autoimmune disease and metastatic cancers. For more information, please visit www.prothena.com .
CONTACT: Paul Cox, Stern Investor Relations, Inc.         212.362.1200, paul@sternir.com

If you liked this article you might like

Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers

Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers

Zogenix Soars After Epilepsy Drug Meets Primary Endpoint -Biotech Movers

Zogenix Soars After Epilepsy Drug Meets Primary Endpoint -Biotech Movers

3 Stocks You Probably Never Heard Of Could Catch Fire Soon

3 Stocks You Probably Never Heard Of Could Catch Fire Soon

Prothena Raises $155.3M to Bring Anti-Organ Failure Drug to Market

Prothena Raises $155.3M to Bring Anti-Organ Failure Drug to Market